Current Epidemiology and Growing Resistance of Gram-Negative Pathogens by Livermore, David M.
review
korean j intern med 2012;27:128-142
http://dx.doi.org/10.3904/kjim.2012.27.2.128 
pISSN 1226-3303    eISSN 2005-6648
http://www.kjim.or.kr
ORIGINAL ARTICLE
Current Epidemiology and Growing Resistance of Gram-
Negative Pathogens
David M. Livermore
1,2
1Norwich Medical School, University of East Anglia, Norwich; 
2Antibiotic Resistance Monitoring & Reference 
Laboratory, Health Protection Agency, London, UK
In the 1980s, Gram-negative pathogens appeared to have been beaten by oxyimino-cephalosporins, carbapenems, 
and fluoroquinolones. Yet these pathogens have fought back, aided by their membrane organization, which promotes 
the exclusion and efflux of antibiotics, and by a remarkable propensity to recruit, transfer, and modify the expression of 
resistance genes, including those for extended-spectrum β-lactamases (ESBLs), carbapenemases, aminoglycoside-
blocking 16S rRNA methylases, and even a quinolone-modifying variant of an aminoglycoside-modifying enzyme. 
Gram-negative isolates -both fermenters and non-fermenters- susceptible only to colistin and, more variably, fosfomycin 
and tigecycline, are encountered with increasing frequency, including in Korea. Some ESBLs and carbapenemases 
have become associated with strains that have great epidemic potential, spreading across countries and continents; 
examples include Escherichia coli sequence type (ST)131 with CTX-M-15 ESBL and Klebsiella pneumoniae ST258 
with KPC carbapenemases. Both of these high-risk lineages have reached Korea. In other cases, notably New Delhi 
Metallo carbapenemase, the relevant gene is carried by promiscuous plasmids that readily transfer among strains and 
species. Unless antibiotic stewardship is reinforced, microbiological diagnosis accelerated, and antibiotic development 
reinvigorated, there is a real prospect that the antibiotic revolution of the 20th century will crumble.
Keywords: Enterobacteriaceae; Pseudomonas; Acinetobacter; β-lactamase; Carbapenemase
Received  : January 30, 2012
Accepted  : April 9, 2012 
Correspondence to David M. Livermore, M.D.
Norwich Medical School, University of East Anglia, Norwich NR4 4TJ, UK
Tel: 44-1603-597568, Fax: 44-20-8327-6264, E-mail: d.livermore@uea.ac.uk
Copyright © 2012 The Korean Association of Internal Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-
commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. 
INTRODUCTION
The ability to treat bacterial infection is critical to 
modern medicine, from abdominal surgery to trans-
plants to cancer management. Without antibiotics, 
these procedures would be unthinkable owing to the in-
fection risk. Yet this ability to beat infection has existed 
for only a brief fraction of human history, beginning 
with the introduction of sulfonamides in the 1930s. 
The ‘antibiotic revolution’ gathered pace from the late 
1940s to the 1960s, with a golden age of natural product 
discovery. This period was followed by two decades of 
repeated successes in modifying natural antibiotics to 
enhance their activity. Subsequently, the flow of new 
antibiotics has dwindled, with diminishing numbers li-
censed in the 1990s and the first decade of this century 
[1,2]. The reasons are threefold: first, the technical dif-
ficulty of discovering new antibiotics, especially those 
able to penetrate Gram-negative bacteria [3,4]; second, 
the regulatory hurdles to new antibiotics which have 
become increasingly complex [5]; and, third, the brutal 
fact that antibiotics, as short-course treatments, are less Livermore DM. Resistance in Gram-negative bacteria    129
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lucrative for the pharmaceutical industry than are long-
term therapies for chronic conditions [6,7].
The lack of new antibiotics is critically important, 
given the continued accumulation of resistance favored 
by Darwinian selection, which erodes the utility of ex-
isting antibiotics. Once a pathogen has been cultured 
some antibiotic retaining activity can usually be identi-
fied, at least in vitro. The greater problem is for empiri-
cal therapy, where growing resistance increases the risk 
that the antibiotic used will prove inactive. In severely 
ill patients, this ineffectiveness leads to increased mor-
tality, length of hospital stay, and cost [8,9]. 
This review considers the extent of emerging and pro-
liferating resistance in Gram-negative bacteria–where 
the problem is most acute–and discusses strategies that 
may be deployed to counter the threat.
GRAM-NEGATIVE BACTERIA
The defining feature of Gram-negative bacteria, 
distinguishing them from Gram-positive species, is a 
double membrane wall (Fig. 1). The outer membrane 
excludes large or hydrophobic molecules, including 
glycopeptides, daptomycin, and rifampicin, and slows 
the entry of drugs that can cross it, augmenting the ef-
fectiveness of the next line of defense. These defenses 
include periplasmic-β-lactamases and cytoplasmic 
membrane efflux pumps, which scavenge amphipathic 
molecules–including antibiotics–that enter the mem-
brane, pumping them back out of the cell [10]. The com-
bination of impermeability and clearance explains why 
Gram-negative bacteria are inherently more resistant 
than Gram-positive species, and why new antibiotics 
active against them are harder to find [3]. Efflux is es-
pecially important in Pseudomonas aeruginosa, which 
has multiple pumps that render it resistant to many 
drug families active against other Gram-negative spe-
cies [11,12]. 
Both Enterobacteriaceae (Escherichia coli, Klebsiella 
spp., Enterobacter spp., Proteus spp., Serratia spp.) 
and non-fermenters (Pseudomonas, Acinetobacter, and 
related genera) are important opportunist pathogens. 
E. coli is–by a large margin–the most common agent 
of community and hospital urinary tract infections and 
the main aerobic component of the mixed flora in intra-
abdominal infections. P. aeruginosa, Klebsiella, and 
Enterobacter are important in nosocomial pneumonia, 
especially in patients with prolonged hospitalization. 
Acinetobacter baumannii is less pathogenic, but notori-
ously causes outbreaks in the most vulnerable patients 
in intensive care units (ICUs). Gram-negative patho-
gens account for around half of all bacteremias, most of 
which arise due to bacterial overspill from other prima-
ry infection sites. In the UK, E. coli is the most common 
agent of bacteremia, causing 30% of all cases, whereas 
P. aeruginosa, Klebsiella spp., Enterobacter spp., and 
Proteeae each account for 4-8% of cases [13]. A few 
Gram-negative species are important classical patho-
gens; those remaining important in developed coun-
tries include Salmonella spp., Haemophilus influenzae, 
Moraxella catarrhalis, Neisseria meningitidis, and N. 
gonorrhoeae. Others ranging from Vibrio cholenzae, to 
Burkholderia pseudomallei remain important in devel-
oping countries, but lie beyond the scope of this review.
ANTI-GRAM-NEGATIVE ANTIBIOTICS
The first anti-Gram-negative antibiotics were sulfon-
amides, introduced in the 1930s; tetracyclines, first-
generation aminoglycosides, and chloramphenicol then 
became available in the late 1940s and early 1950s, 
respectively. Two quantum leaps followed. The first de-
livered semi-synthetic penicillins and first-generation 
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Figure 1. Outer layers of the Gram-negative cell. To reach its 
target, the antibiotic must diffuse across the outer membrane, 
normally via porins, which form water-filled channels and 
exclude large or hydrophobic molecules. The drug must then 
evade periplasmic β-lactamases and efflux pumps; depending on 
its target, it may also need to cross the cytoplasmic membrane, 
often by energy-dependent uptake.130    The Korean Journal of Internal Medicine Vol. 27, No. 2, June 2012
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cephalosporins in the early 1960s, along with more 
potent and less toxic aminoglycosides such as gentami-
cin and amikacin. The second, in the 1980s, led to the 
development of third- and fourth-generation oxyimino-
cephalosporins, β-lactamase-inhibitor combinations, 
carbapenems, and fluoroquinolones. These drug 
families are now standard therapies for severe Gram-
negative infections, but growing resistance has created 
the present problem, as few new agents have been de-
veloped to replace them.
Resistance in Enterobacteriaceae, internationally 
and in Korea
At launch, third-generation cephalosporins were 
almost universally active against Enterobacteriaceae; 
ceftazidime was also active against P. aeruginosa and, 
often, A. baumannii. Resistance emerged first in En-
terobacter spp. (especially), Citrobacter freundii, and 
Serratia spp., all of which have inducibly-expressed 
chromosomal AmpC β-lactamases. Third-generation 
cephalosporins are labile to these enzymes but are weak 
inducers of their synthesis. The result is that cepha-
losporins kill the AmpC-inducible cells but confer an 
advantage upon spontaneous ‘derepressed’ variants that 
express AmpC activity without induction [14]. These 
variants arise by spontaneous mutation in inducible (i.e., 
normal) strains, and the likelihood of their selection 
during therapy, with consequent treatment failure, is as 
high as 20-30% when third-generation cephalosporin 
is used to treat an Enterobacter bacteraemia [15]. Se-
lection is associated with a doubling of mortality and a 
50% increase in hospital stay and doubling of cost for 
survivors (Table 1) [16]. Piperacillin-tazobactam is also 
compromised, but seems to be less often associated 
with selection than are third-generation cephalospo-
rins, although the reasons for this difference remain 
uncertain and one analysis did find similar selectivity 
[17]. Fourth-generation cephalosporins (cefepime and 
cefpirome) and carbapenems are more stable and less 
selective (Table 2).
Genes encoding AmpC β-lactamases have escaped 
from the chromosomes of Citrobacter and other gen-
era to plasmids and are now circulating in E. coli and 
Klebsiella pneumoniae [18]. The enzymes they encode 
are variously called CMY, FOX, MOX and MIR types 
or, more usefully, ‘plasmid AmpC.’ Extended-spectrum 
β-lactamases (ESBLs) represent the second and greater 
plasmid-mediated threat to oxyimino-cephalosporins, 
affecting fourth- as well as third-generation analogues 
(Table 2). The earliest ESBLs, first identified in the 
1980s, were mutants of the plasmid-borne TEM and 
SHV penicillinases that had disseminated in E. coli and 
other Enterobacteriaceae in the 1960s and 1970s [19]. 
Although third-generation cephalosporins are stable to 
classical TEM and SHV enzymes, over 200 ESBL mu-
tants have been identified, with sequence changes that 
expand the active site, allowing attack on oxyimino-
cephalosporins (see http://www.lahey.org/studies for 
a list). Many variants have been described only once or 
twice, but SHV-2, -5, -11, and -12 and TEM-3, -10, -26, 
-52, and -116 are widespread in many countries [20,21]. 
TEM and SHV ESBLs spread during the 1980s and 
1990s, largely in Klebsiella spp. and particularly in 
ICUs [19,22]. Some strains caused major outbreaks, but 
did not substantially penetrate E. coli strains or spread 
in the community. This is surprising because E. coli 
strains with the progenitor TEM-1 enzyme are frequent 
in the human gut and must have been exposed to huge 
amounts of ceftriaxone, which was long the most widely 
used injectable antibiotic and has biliary excretion. 
These ESBLs may thus present a burden to E. coli, but 
this aspect remains to be properly explored.
A massive shift in the distribution of ESBLs has oc-
curred since 2000 with the spread of CTX-M types–a 
decade earlier in Argentina [23]. Unlike TEM and SHV 
variants, these ESBLS are not mutants of old plasmid-
mediated penicillinases. Rather, their genes originated 
in the chromosomes of Kluyvera spp., a genus of no 
direct clinical importance, and were mobilized to plas-
mids by insertion sequences, notably ISEcp1 [24,25]. 
Plasmids encoding these CTX-M enzymes then reached 
human opportunists, where they have proliferated in 
community E. coli and hospital Klebsiella spp. Gene es-
cape has occurred repeatedly, with five CTX-M families 
(groups 1, 2, 8, 9, and 25) circulating. Different CTX-M 
families dominate in different places: CTX-M-15 (group 
1) is predominant in most of Europe, North America, 
the Middle East, and India, but CTX-M-14 (group 9) is 
most common in China, Southeast Asia, and Spain, and 
CTX-M-2 (group 2) is predominant in Argentina, Israel, 
and Japan [20,22]. 
The prevalence of ESBLs (CTX-M and other types) Livermore DM. Resistance in Gram-negative bacteria    131
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Table 1. Consequences of selection of AmpC-
derepressed mutants during cephalosporin treatment 
of Enterobacter infections
Case Control
Mortality, % 26  13
Mean hospital stay, day 29.5 19 
Median cost, US$ 79,000 40,000
Cases exhibited selection of AmpC-derepressed mutants during 
cephalosporin treatment of Enterobacter infections; controls are 
those in whom cephalosporins were used successfully, without 
selection of resistance [16].
differs among patient groups and clinical and geo-
graphic settings. In the UK, around 10% of E. coli from 
bacteremias now have ESBLs -90% of them CTX-M 
types [26]- and producers are frequent in urinary iso-
lates from geriatric patients, although denominators 
are poor, precluding accurate prevalence estimates. By 
contrast, their prevalence is ≤ 1% in community cystitis. 
Gut carriage of ESBL E. coli was seen in 40% of nursing 
home residents in Belfast (Northern Ireland), providing 
a reservoir for future urinary or intra-abdominal infec-
tions–which are frequent in these vulnerable patients–
but in only 1-2% of other outpatients whose stools were 
examined by the clinical laboratory [27]. Many studies 
have shown that community infections with ESBL E. 
coli predominantly affect older (> 65 years) patients 
with recent hospitalization and antimicrobial treat-
ment, especially with cephalosporins or quinolones [28]. 
Travel in high-prevalence countries is a risk factor for 
gut colonization by ESBL E. coli, with travel-associated-
strains sometimes causing later urinary infections [29].  
The variability in ESBL rates among population 
groups should prompt caution when viewing national 
prevalence rates; these benchmark values are of less 
clinical importance than local rates in different patient 
groups. Despite this caveat, a rough international pic-
ture can be drawn. Multiple surveys have shown that 
the highest ESBL rates for E. coli and Klebsiella spp. oc-
cur in India (≥ 80%) and China (≥ 60%), [30-32], with 
rates ≥ 30% elsewhere in East and Southeast Asia, Latin 
America, and Southern Europe vs. 5-10% in Austral-
asia, Northern Europe, and North America [30]. Some 
studies have suggested that ESBL prevalence in India 
is equally high in community and hospital E. coli iso-
lates [31], probably reflecting unregulated antibiotic use 
coupled with recycling of gut bacteria by an overloaded 
sewage infrastructure [33,34]. In Hong Kong, ESBLs 
were found in 7.3% of E. coli from uncomplicated com-
munity cystitis, including in 11/219 isolates from women 
aged 18-35 years, a much younger age group than typi-
cally affected by ESBL E. coli elsewhere [35]. A growing 
number of ESBL outbreaks has also been reported in 
neonatal units, likely due to the transfer of E. coli from 
the gut flora of one mother to her infant at birth, fol-
lowed by spread among other infants in the unit [36,37]. 
The epidemiology of CTX-M ESBLs involves both 
plasmid dissemination and clonal success. CTX-M-15–
the most prevalent enzyme–is most often encoded by 
IncF plasmids that are prone to multiple rearrange-
ments [38]. In the case of K. pneumoniae, these plas-
mids are carried by diverse strains; some strains cause 
Table 2. Ability of β-lactamases to confer resistance 
Ampicillin
/piperacillin
Cefotaxime
/ceftriaxone
Ceftazidime
Cefepime
/cefpirome
Aztreonam
Imipenem
/meropenem
Amox-clav
pip-tazo
Hyperproduced AmpC RRR RR RR R RR -
a RR
Classical TEM/SHV RRR - - - - - If hyperproduced or 
 accompanied by inhibitor 
 resistant enzyme, e.g., OXA
TEM/SHV ESBL RRR RR RR RR RR -
a
CTX-M ESBL RRR RRR R(R) RR RR -
a
KPC RRR RR RR RR RR RR RR
IMP/VIM/NDM RRR RRR RRR RRR -
b RR RR
OXA-48 RRR R
b -
b R
b R R(R) RRR
RRR, high-level resistance always seen; RR, resistance usually clear; R, MICs raised but may or may not exceed breakpoint;
-, resistance not normally seen. 
ESBL, extended-spectrum β-lactamase.
aResistance arises if combined with impermeability. 
bResistance widespread as producers often also have ESBLs.132    The Korean Journal of Internal Medicine Vol. 27, No. 2, June 2012
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local outbreaks but none has achieved wider success 
[39]. In E. coli, however, CTX-M-15-encoding IncF 
plasmids are strongly associated with a sequence type 
(ST)131 lineage, now widespread globally [25,40] (Fig. 
2). It remains unclear whether a progenitor ST131 strain 
acquired an original IncF-CTX-M-15 plasmid and then 
spread while diversifying, or whether ST131–a lineage 
that dates back to the 1980s–has repeatedly acquired 
IncF-CTX-M-15 plasmids at different times in different 
places, perhaps with considerable exchange to and from 
Klebsiella. E. coli ST131 occasionally hosts other ESBLs 
besides CTX-M-15: in Belfast (Northern Ireland, UK) 
it often has the IncI1 plasmid, pEK203, encoding CTX-
M-3. CTX-M-3 differs from CTX-M-15 by only a single 
amino acid change and the two enzymes can intercon-
vert by mutation: nevertheless, the sequences flanking 
blaCTX-M-3 in pEK203 differ from those flanking blaCTX-
M-15 in its typical IncF plasmid hosts, e.g., pEK499 and 
pEK516 [41,42], showing that they reflect separate gene 
escapes from Kluyvera. CTX-M-14 ESBL, which domi-
nates in the Far East, is not strongly associated with 
ST131 or other successful clones, and its accumulation 
largely entails plasmid spread among strains.
ESBLs achieved a high prevalence before 2000 in 
Korea; otherwise, the pattern appears similar to that 
elsewhere, with CTX-M ESBL types replacing TEM and 
SHV. In a review of studies published before 1998, Pai 
[43] estimated ESBL prevalence rates of 4.8-7.5% in E. 
coli and 22.5-22.8% in K. pneumoniae, with TEM-52 
dominant in E. coli and SHV-2 and -12 in K. pneumoni-
ae. Plasmid-mediated CMY-1 (AmpC) was estimated to 
occur in 15% of Enterobacteriaceae–an exceptionally 
high rate [43]. These results were broadly supported 
by a survey of 13 hospitals by Jeong et al. [44] in 2002, 
which found SHV-2a and -12 and TEM-19, -20, -52, and 
-116 to be the main ESBLs, although the prevalence of 
CMY-1 was much lower than Pai [43] had suggested. 
CTX-M ESBLs were first reported in Korea in 2005 
[45] and are now predominant [46]: CTX-M-14 and -15 
are both widespread [46,47]. As elsewhere, CTX-M-15 
is strongly associated with E. coli ST131 [48], whereas 
CTX-M-14 is disseminated among strains [47]. Infec-
tion risk factors for ESBL producers resemble those 
found internationally, including prior healthcare and 
antibiotics [49,50]. More exceptional–but recapitulating 
the Hong Kong data [35]–is a 2006 multicenter survey 
finding of ESBLs in 11.8% of E. coli from uncomplicated 
cystitis [51]. A subsequent study of isolates collected in 
2008-2009 found a lower (6.4%) rate of cephalosporin 
resistance in E. coli from cystitis, although the authors 
noted that ciprofloxacin resistance continued to in-
crease from 15.2% in 2002 to 23.4% in 2006 and 24.8% 
in 2008-2009 [52]. 
Many ESBL producers in Korea and elsewhere are 
multiresistant to non-β-lactam antibiotics, including 
fluoroquinolones and aminoglycosides [20,23,53]. The 
main factors in quinolone resistance are combinations 
of mutations affecting the chromosomal topoisomerase 
genes gyrA and parC. Resistance to other antibiotics, 
including trimethoprim, tetracyclines, sulfonamides, 
and chloramphenicol as well as aminoglycosides is often 
encoded by the same plasmids that determine the ESBL. 
IncF plasmids encoding CTX-M-15 ESBL often also de-
termine AAC(6’)-Ib-cr, which inactivates amikacin and 
tobramycin (not gentamicin) and also deactivates cip-
rofloxacin, augmenting resistance [54]. These plasmids 
also often encode OXA-1, an inhibitor-resistant penicil-
linase, conferring resistance to piperacillin-tazobactam 
and amoxicillin-clavulanate, even though these inhibi-
tors inactivate CTX-M-15 [41,55]. 
Most aminoglycoside resistance among Enterobacte-
riaceae in the West is determined by aminoglycoside-
modifying enzymes like AAC(6’)-1b. These enzymes are 
also common in Asia, but wide circulation of the ArmA 
and RmtA-C 16S ribosomal RNA (rRNA) methylases is 
also found in Asia, unlike in Europe and the US [56-58]. 
These methylases modify bacterial ribosomes to block 
binding of all key aminoglycosides, including the new 
analogue ACHN-490 [59]. They are widespread in Ko-
rea and are commonly carried by plasmids that also en-
code SHV-12 and CTX-M-14 ESBLs, but have not been 
associated with CTX-M-15 or E. coli ST131 [60,61]. 
Carbapenem resistance
The growing prevalence of cephalosporin-resistant En-
terobacteriaceae is driving the directed and empirical use 
of carbapenems, as the only widely marketed β-lactams 
stable to ESBLs and AmpC enzymes (Table 2).
Carbapenems retained near-universal activity against 
Enterobacteriaceae for around 20 years after the intro-
duction of imipenem in 1985, but resistance is now ac-
cumulating. It can evolve by porin loss, reducing drug Livermore DM. Resistance in Gram-negative bacteria    133
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Figure 2. International spread of Escherichia coli ST131 
[25,40] . This strain has played a major role in the dissemination 
of CTX-M-15 extended-spectrum β-lactamase (ESBL), but 
occasionally hosts other types. It occurs in Korea, where 
CTX-M-14 ESBL (not linked to a particular clone) is also 
widespread [48]. 
Figure 3. International dissemination of ST258 Klebsiella 
pneumoniae with KPC carbapenemases [68]. This lineage occurs 
internationally and has been reported in Korea [85]. 
entry in strains already containing high levels of AmpC 
or an ESBL [62]. This is a common source of low-level 
resistance to ertapenem, especially in Enterobacter and 
Klebsiella, with resistant variants sometimes selected 
during carbapenem therapy [63]. However, this problem 
is limited because these variants are often unstable and 
tend to revert to susceptibility, rarely spreading among 
patients [64,65]. Their porin deficiency likely impedes 
nutrition, reducing competitiveness.
Much more concerning is the gradual proliferation 
of carbapenemases, which are biochemically diverse 
and include members of three of the four β-lactamase 
classes (A, B, D). 
KPC enzymes (class A, non-metallo) are currently the 
predominant carbapenemases emerging in Enterobacte-
riaceae [66]. They were first recorded in North Carolina 
(USA) in 1997, with outbreaks in New York by 2005. 
Since 2006, KPC
+ K. pneumoniae have spread across 
the USA and in Israel, Greece, and, latterly, Italy, with 
growing outbreaks in China, Brazil, and several Euro-
pean countries. The highest national prevalence rate (to 
40%) is for K. pneumoniae from bacteremias in Greece 
[67]. Much of this spread reflects an association of KPC 
enzymes with a successful clone, K. pneumoniae, ST258 
(Fig. 3) [68]. Members of this lineage are typically re-
sistant to all antibiotics except colistin, tigecycline, and 
gentamicin. A colistin-resistant variant of ST258 is cir-
culating in Greece [69], with cases also seen, possibly 
via import, in Hungary and the UK [70]. The reasons for 
the particular success of ST258 are uncertain, but its 
ability to spread swiftly is beyond dispute. In addition, 
KPC enzymes have spread considerably via plasmids 
among different K. pneumoniae strains and other En-
terobacteriaceae, principally E. coli and Enterobacter 
spp.
Metallo-carbapenemases (class B) are biochemically 
very different from KPC, and include IMP, VIM, and 
New Delhi Metallo (NDM) enzymes, along with less 
frequently occurring families. IMP was recognized in 
Japan at the end of the 1980s [71] and has gradually 
spread worldwide, although it has not achieved great 
prevalence anywhere. VIM is more important; it was 
first recorded in P. aeruginosa in Verona (Italy) in 1997 
[72] and then spread into Enterobacteriaceae, princi-
pally K. pneumoniae. By 2005, it was present in 40% of 
bloodstream K. pneumoniae from Greece, where it has 
subsequently been partly displaced by KPC enzymes 
[73]. 
Clusters of K. pneumoniae with VIM carbapenemases 
are increasingly being reported worldwide, although 
they are less numerous than isolates with KPC enzymes. 
A further distinction is that VIM enzymes are not asso-
ciated with any particular clone, whereas KPC enzymes 
are associated with ST258 K. pneumoniae. Although 
local outbreaks occur, the larger issue is the dissemina-
tion of blaVIM among K. pneumoniae, largely by IncN 
plasmids [73,74]. 
NDM–the most publicized metallo-carbapenemase–is 
epicentered in India, where it occurs in 2-8% of Entero-
bacteriaceae at teaching hospitals [75,76], and in Paki-134    The Korean Journal of Internal Medicine Vol. 27, No. 2, June 2012
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stan, where 27% of inpatients at two military hospitals 
were carriers. blaNDM-1, encoding the enzyme, is wide-
spread in surface-water bacteria in New Delhi, implying 
community circulation. Enterobacteriaceae (and occa-
sionally Acinetobacter spp.) with NDM carbapenemase 
have repeatedly been imported into Europe, Asia, North 
America, and Australasia by those who have travelled 
or been hospitalized in the Indian subcontinent [77]. As 
with VIM metallo-carbapenemases, spread is largely by 
plasmid transfer, not clonal dissemination [77]. 
The final and very different-emerging carbapenemase 
of Enterobacteriaceae is OXA-48, reported in Turkey 
since 2001, mostly in K. pneumoniae. It has dissemi-
nated in the Middle East and North Africa since 2007-
2008, with repeated import into Europe; outbreaks 
have occurred in the UK, Belgium, Ireland, France, 
Spain, and The Netherlands (Fig. 4) [78,79]. The main 
factor in its spread is dissemination of 50- and 70-
kb plasmids carrying the blaOXA-48 transposon Tn1999 
among Klebsiella strains [80]. A related enzyme, OXA-
181, is circulating in India, where it seems less frequent 
than NDM-1 [81]. OXA-48 and -181 originated by sepa-
rate mobilizations of chromosomal β-lactamase genes 
from Shewenella, a genus otherwise lacking clinical 
importance [79]. 
To date, carbapenemase-producing Enterobacteria-
ceae have shown little circulation in Korea, although 
C. freundii and S. marcescens with VIM-2 [82] and 
K. pneumoniae [83] with KPC enzymes have been re-
ported, and a very recent report described an outbreak 
cluster of K. pneumoniae with the NDM-1 enzyme [84]. 
Unusually, an S. marcescens strain with AmpC and im-
permeability caused an outbreak involving nine patients 
at a hospital in Seoul [65]. Most disturbing is the recent 
appearance of KPC
+ K. pneumoniae ST258. Only one 
producer has been reported to date [85], from a urinary 
infection in Seoul, but this development should raise 
concern, given the strain’s dramatic success elsewhere.
KPC carbapenemases inactivate all β-lactams. Az-
treonam is stable to the IMP, VIM, and NDM types, but 
these are often accompanied by aztreonam-hydrolyzing 
ESBLs. Similarly, although OXA-48 spares ceftazidime, 
it is often accompanied by ceftazidime-hydrolyzing ES-
BLs (Table 2). Resistance to non-β-lactams is variable, 
but many carbapenemase producers are susceptible 
only to colistin, tigecycline, and/or fosfomycin, none of 
which is an ‘ideal’ antibiotic. NDM carbapenemases are 
often accompanied by the 16S rRNA methylases men-
tioned earlier, compromising the widest range of ami-
noglycosides [59,81]. 
Non-fermenters
The prevalence of resistance in P. aeruginosa varies 
widely among countries. In Europe, resistance rates to 
aminoglycosides, carbapenems, cephalosporins, and 
fluoroquinolones are lowest (< 10%) in the northwest, 
particularly in Scandinavia, and highest (25-50%) in the 
southeast, particularly in Greece [86]. Rates are high in 
Latin America and Southeast Asia, and intermediate in 
the US [87]. 
Most resistance among P. aeruginosa in Europe and 
North America involves mutations that restrict drug en-
try (the most common cause of carbapenem resistance), 
derepress chromosomal AmpC (as in Enterobacter, 
above) and up-regulate efflux [88,89]. Acquired mecha-
nisms are more important in resistance in Asia and Lat-
in America and include different ESBLs to those most 
prevalent in Enterobacteriaceae, notably PER-1, which is 
widespread in Turkey [90], and VEB-1, which first pro-
liferated in Southeast Asia [91]. Metallo-β-lactamases 
are scattered and single-hospital outbreaks due to pro-
ducers have occurred worldwide (Fig. 5) [92,93]. These 
OXA-48, 2001-8
OXA-48, 2008 onwards
OXA-181  and -163
Figure 4. Spread of OXA-48 and related carbapenemases. Until 
2007-2008, the OXA-48 enzyme was confined to Turkey. Carried 
by 50- and 70-kb plasmids, it has since spread to North Africa, 
the Middle East, and, increasingly Europe. A related enzyme, 
OXA-181, is circulating in India, but is rarer than the NDM-1 
metallo-carbapenemase. These enzymes have not yet reached 
Korea.Livermore DM. Resistance in Gram-negative bacteria    135
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outbreaks are often prolonged, with cases scattered over 
long periods, probably owing to persistence in the hos-
pital structure, e.g., in sink traps. In Brazil, a clone with 
São Paolo Metallo (SPM)-β-lactamase has disseminated 
among hospitals, achieving national distribution [94]. 
Elsewhere, P. aeruginosa ST111, which corresponds to 
serotype O12 and ‘burst group 4,’ is now a common host 
to VIM metallo-carbapenemases [68]. This lineage has 
a long history of acquiring resistance -20 years ago it 
often carried the PSE-1 carbenicillinase [95]. ST235 (se-
rotype 11) is also a successful accumulator of resistance, 
frequently hosting IMP and VIM carbapenemases [68]. 
A 2005 survey of 23 hospitals in Korea found carbap-
enemases in 10% of carbapenem-resistant P. aerugi-
nosa, with VIM types 2.5-fold more common than IMP 
types [96]. The remaining 90% of carbapenem-resistant 
P. aeruginosa were inferred to have impermeability-
type resistance. Subsequently, an ST235 clone with the 
IMP-6 enzyme has disseminated nationally [97]. In a 
2009 survey of 21 hospitals, this strain accounted for 
30/386 (7.8%) isolates and was recovered in 14 sites. As 
with NDM-1 in Enterobacteriaceae, blaIMP-6 in Korean 
P. aeruginosa is often associated with the ArmA rRNA 
methylase [98].
The molecular epidemiology of A. baumannii, another 
important opportunistic non-fermenter, contrasts to 
that of P. aeruginosa, with resistance largely originat-
ing from the up-regulation of inherent chromosomal 
AmpC and carbapenemase (blaOXA-51) genes by insertion 
sequences, critically ISAba1, which migrate within the 
chromosome [99,100]. The insertion of ISAba1 in front 
of one of these β-lactamase genes provides an efficient 
promoter, allowing expression and resistance. Alterna-
tively, resistance can be caused by acquired OXA-23, 
-40, and -58 carbapenemases [99]. OXA-23 originated 
as a chromosomal carbapenemase in Acinetobacter 
radioresistens [101], a species with no direct clinical im-
portance.
OXA carbapenemases account for most carbapenem 
resistance in A. baumannii worldwide, including in 
Korea, where the resistant proportion reportedly grew 
from 13% in 2003 to 51% in 2008-2009, and where two 
carbapenemase-producing clones are in wide circula-
tion among hospitals, one with OXA-23 and frequent 
colistin resistance, the other with up-regulated OXA-51 
[102]. 
Metallo-carbapenemases also occur, with NDM re-
corded in A. baumannii (although not yet in Korea) and 
IMP in non-baumannii species, but these are extremely 
rare compared with OXA types [103]. A unique metallo- 
type, Seoul imipenemase (SIM-1), has been described 
from A. baumannii in Korea, but it has not disseminat-
ed [104]. 
As in Enterobacteriaceae, most resistance to non-β-
lactams depends on acquired genes–not on mutation, 
as in P. aeruginosa. Acquired genes may be carried by 
plasmids or by massive ‘resistance islands’ inserted into 
the chromosome [105,106]. Colistin resistance, as in one 
of the prevalent Korean clones, can arise via changes 
to membrane phospholipids and lipopolysaccharides 
[107,108], and resistance to tigecycline by up-regulation 
of the chromosomal AdeB efflux pump is sometimes se-
lected for during therapy [109]. 
Fastidious Gram-negative bacteria
A few N. meningitidis and H. influenzae isolates 
have low-level resistance to fluoroquinolones, whereas 
resistance to third-generation cephalosporins has not 
been seen in either species. N. meningitidis shows only 
slightly reduced susceptibility to penicillin, even after 
70 years of use.
N. gonorrhoeae, by contrast, has sequentially de-
veloped resistance to low-level penicillin, high-level 
penicillin, and ciprofloxacin, with borderline non-
susceptibility to cefixime (MICs, 0.12-0.5 mg/L) now 
"'
VIM
IMP
SPM
Figure 5. Reported outbreaks due to metallo-β-lactamase-
producing Pseudomonas aeruginosa. Most carbapenem 
resistance in P. aeruginosa, including in Korea, is due to porin 
loss, but carbapenemase producers occur and may be strongly 
persistent in some hospitals. Korea has a particular concern 
regarding a nationally distributed strain that harbors the IMP-6 
enzyme [97].136    The Korean Journal of Internal Medicine Vol. 27, No. 2, June 2012
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proliferating [110], including in Korea [111,112]. This 
development is driving a treatment shift to high-dose 
ceftriaxone, sometimes (as in the UK) combined with 
azithromycin [113]. Few other options are available if 
substantial resistance to these treatments emerges and, 
disturbingly, two reports have described gonococci with 
resistance to ceftriaxone and cefixime: one from Japan 
[114] and the other from France [115]. The first patient 
developed an oropharyngeal infection and recovered–
perhaps spontaneously–during a second course of cef-
triaxone; the second developed a urethral infection that 
was cured with gentamicin.
THE FUTURE
The range of antibiotic options to treat Gram-positive 
infections, particularly those due to MRSA, has expand-
ed in the past decade with the introduction of quinu-
pristin-dalfopristin, linezolid, daptomycin, tigecycline, 
and, in some markets, telavancin and ceftaroline. Ad-
ditional agents, including oritavancin, dalbavancin, and 
tedizolid (torezolid), are in phase III development and 
are anticipated in the next 2-3 years. Among these new 
anti-MRSA agents, only tigecycline shows any increase 
in in vitro anti-Gram-negative activity compared with 
previous members of its chemical family (tetracyclines), 
and its efficacy in severe infections is variable, with low 
serum levels and disappointing results in nosocomial 
pneumonia [116]. The only other anti-Gram-negative 
agent launched in the past decade is doripenem, which 
represents an incremental improvement over merope-
nem in anti-Pseudomonas activity, but is otherwise 
similar [117]. 
In short, little progress against Gram-negative bacte-
ria has been made for a long time. Nevertheless, several 
new anti-Gram-negative agents are in phase III devel-
opment and show promise. CXA-201, a cephalosorin 
(ceftolozane)-tazobactam combination, is four-fold 
more active than ceftazidime–still the best anti-pseu-
domonal cephalosporin–against P. aeruginosa [118,119]. 
Ceftazidime-avibactam, another new inhibitor combi-
nation, is active against strains with AmpC, ESBLs, and 
KPC or OXA-48 carbapenemases [120], and the neogly-
coside plazomicin overcomes nearly all aminoglycoside-
modifying-enzyme-mediated resistance [121]. 
Nevertheless, each of these agents has gaps in its 
spectrum, and none provides such complete coverage as 
ceftazidime, imipenem, and ciprofloxacin did when they 
were introduced 20-30 years ago. CXA-201 lacks activ-
ity against Enterobacteriaceae with metallo- and KPC 
carbapenemases and shows borderline activity against 
some ESBL and AmpC producers [122]; ceftazidime-
avibactam lacks activity against strains with metallo-
carbapenemases, such as VIM and NDM [120]; and 
plazomicin fails to overcome resistance mediated by 
ArmA and Rmt rRNA methylases [59]. 
Other antibiotics in earlier developmental stages may 
offer a more comprehensive solution. The most prom-
ising are 1) boron-based protein synthesis inhibitors 
(GSK-Anacor partnership) [123]–though their develop-
ment was recently suspended, 2) fluorine-containing 
tetracyclines (‘fluorocyclines,’ Tetraphase) [124], and 3) 
novel protein synthesis inhibitors (RibX-Sanofi part-
nership). Aztreonam-avibactam shows the potential to 
overcome both metallo- and non-metallo-carbapen-
emases [120]; it is not yet under formal development 
but would be relatively easy to progress, following ex-
perience with ceftazidime-avibactam and ceftaroline-
avibactam.
However, these drugs will only be available in the 
future, and licensing success is not guaranteed. There-
fore, as much as possible must be done through good 
stewardship and infection control to prolong the life 
of existing antibiotics. Improvements in laboratory 
microbiology and its interaction with patient manage-
ment are also critical. Currently, a 48-hour interval–at 
the very best–remains between the clinical diagnosis 
of a patient’s infection and the clinician’s acquisition of 
laboratory results indicating the isolate’s susceptibility. 
During this interval the patient is treated empirically 
based on the likely pathogens and local resistance rates. 
Such treatment becomes more difficult as resistance 
increases, and multiple studies have shown that resis-
tance to the empirical regimen leads to a near doubling 
of mortality in bacteremias [8]. One response is to start 
patients on the most powerful empirical antibiotic, 
typically a carbapenem combined with an anti-MRSA 
agent, and to ‘de-escalate’ once laboratory microbiology 
results are available [125,126]. Although this strategy 
improves initial coverage, which may benefit the patient 
[127], it has two pitfalls: first, hospitals frequently fail Livermore DM. Resistance in Gram-negative bacteria    137
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to enforce de-escalation when a susceptible pathogen is 
isolated; second, the approach does not specify the ap-
propriate response when the patient still shows symp-
toms of infection but no pathogen is isolated. Both fac-
tors potentially lead to unnecessarily prolonged use of 
the broadest-spectrum agents, increasing the selection 
of resistance. The situation would be improved if micro-
biology could be accelerated, identifying pathogens and 
their resistances in hours rather than days, and with-
out the need for culture [128]. Potential methods exist, 
including polymerase chain reaction or DNA arrays to 
seek species- and resistance-specific genes [129,130]. 
Nevertheless, great challenges remain, especially with 
non-sterile-site specimens, in which DNA extracted 
from the pathogen becomes mixed with that from com-
mensals.
If these challenges can be overcome–perhaps first for 
blood and other sterile-site specimens–results can be 
delivered to the ward far more swiftly. Such develop-
ment would reduce the conflict between the individual, 
who currently may benefit from receiving the most 
powerful antibiotics, and society, which benefits if they 
are conserved. This goal is surely worthwhile because 
the alternative is a world where high-tech medicine 
becomes ever more hazardous as–owing to proliferat-
ing resistance–it becomes increasingly more difficult to 
treat infection empirically.
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